Pharmaceuticals (Jul 2021)

Primary and Metastatic Brain Tumours Assessed with the Brain and Torso [<sup>18</sup>F]FDG PET/CT Study Protocol—10 Years of Single-Institutional Experiences

  • Agata Pietrzak,
  • Andrzej Marszałek,
  • Tomasz Piotrowski,
  • Adrianna Medak,
  • Katarzyna Pietrasz,
  • Julia Wojtowicz,
  • Hubert Szweda,
  • Krzysztof Matuszewski,
  • Witold Cholewiński

DOI
https://doi.org/10.3390/ph14080722
Journal volume & issue
Vol. 14, no. 8
p. 722

Abstract

Read online

According to the international societies’ recommendations, the 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) technique should not be used as the method of choice in brain tumour diagnosis. Therefore, the brain region can be omitted during standard [18F]FDG PET/CT scanning. We performed comprehensive literature research and analysed results from 14,222 brain and torso [18F]FDG PET/CT studies collected in 2010–2020. We found 131 clinically silent primary and metastatic brain tumours and 24 benign lesions. We concluded that the brain and torso [18F]FDG PET/CT study provides valuable data that may support therapeutic management by detecting clinically silent primary and metastatic brain tumours.

Keywords